<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|
|---|---|---|
|Remission induction for active, severe disease| | |
|Ungraded position statement: For patients with active, severe EGPA, either IV pulse GCs or high-dose oral GCs may be prescribed as initial therapy.|3|Very low|
|Ungraded position statement: For patients with active, severe EGPA, either cyclophosphamide or rituximab may be prescribed for remission induction.|4|Very low|
|Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclophosphamide or rituximab over mepolizumab for remission induction.|6, 7|Low|
|Remission induction for active, nonsevere disease| | |
|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and GCs over methotrexate, azathioprine, or mycophenolate mofetil and GCs.|8, 9, 10, 13|Very low to low|